CONSUMER HEALTHCARE PRODUCTS ASSOCIATION for CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 -- To reauthorize certain programs under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to public health security and all-hazards preparedness and response, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes. H.R.648 - Consolidated Appropriations Act, 2019 -- Making appropriations for the fiscal year ending September 30, 2019, and for other purposes. Includes language authorizing the collection of Monograph Reform user fees. H.J.Res.28 - Further Additional Continuing Appropriations Act, 2019 - This joint resolution provides continuing FY2019 appropriations to several federal agencies through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. H.J.Res.31 - Consolidated Appropriations Act, 2019 -- This joint resolution provides continuing FY2019 appropriations for the Department of Homeland Security (DHS) through the earlier of February 15, 2019, or the enactment of the applicable appropriations legislation. It is known as a continuing resolution (CR) and ends the partial DHS shutdown that began on December 22, 2018, because the existing CR expired and the FY2019 DHS appropriations bill has not been enacted. H.R.268 - Supplemental Appropriations Act, 2019 -- This bill provides $12.1 billion in FY2019 supplemental appropriations to several federal departments and agencies for expenses related to the consequences of recent wildfires, hurricanes, volcanos, earthquakes, typhoons, and other natural disasters. S.726 - Personal Care Products Safety Act -- To amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. Cosmetic Safety Enhancement Act of 2019 (Pallone/Shimkus discussion draft) -- To amend the Federal Food, Drug, and Cosmetic Act to improve cosmetic safety, and for other purposes H.R.3443 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 S.1895 - Lower Health Care Costs Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.4296 - Safe Cosmetics and Personal Care Products Act of 2019 Udall/Lowenthal consumer products plastics outline, proposal to address consumer plastics issues. No bill number. H.R.2296/S.1391 - More Efficient Tools to Realize Information for Consumers Act S.2740 - Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5279 - Cosmetic Safety Enhancement Act of 2019 21st Century Cures Act 2.0 (No bill number) H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R.748 - CARES Act Critical infrastructure and supply chain HR 8837 -- Continuing Appropriations Act, 2021 and Other Extensions Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
| DAVID CHARLES SPANGLER | — |
Alcohol and Drug Abuse ALC
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
| DAVID CHARLES SPANGLER | — |
Taxation/Internal Revenue Code TAX
S.12 - Health Savings Act of 2019 - Makes changes to Health Savings Accounts and Flexible Spending Accounts to include eligibility for OTC medicines and dietary supplements. H.R. 1922/S.1089 - The Restoring Access to Medication Act -- To amend the Internal Revenue Code of 1986 to include certain over-the-counter medical products as qualified medical expenses. S.3129 - Lower Costs, More Cures Act of 2019 S.3112 - Personalized Care Act of 2019 H.R.748 - CARES Act Legislation to expand access to dietary supplements via HSA/FSA eligibility H.R.7242 - To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts for gym memberships and costs of home gym equipment, to repeal the requirement that health plan be high deductible, and for other purposes. S.4463 - A bill to amend the Internal Revenue Code of 1986 to include certain over-the-counter dietary supplement products as qualified medical expenses
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
Environment/Superfund ENV
H.R.1834 - To direct the Secretary of Commerce to issue regulations prohibiting the use of sunscreen containing oxybenzone or octinoxate in a National Marine Sanctuary in which coral is present, and for other purposes. S.1371/H.R. 2588 - Oxybenzone and Octinoxate Impact Study Act of 2019 H.R.2587/S. 1375 - Reef Safe Act of 2019 S.3263/H.R.5845 - Break Free From Plastic Pollution Act of 2020
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
Food Industry (safety, labeling, etc.) FOO
Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. (no bill number) H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 S.1215 - National Defense Authorization Act for Fiscal Year 2020 S.2032 - A bill to expand research on the cannabidiol and marihuana. S.1717/H.R. 3142 - SNAP Vitamin and Mineral Improvement Act of 2019 H.R.1887 - National Institute of Nutrition Act H.R.1595 - Secure And Fair Enforcement Banking Act of 2019 S.2895 - SARMs Control Act of 2019 S.1790 - National Defense Authorization Act for Fiscal Year 2020 H.R.1865 - Further Consolidated Appropriations Act, 2020 H.R.5587 - To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
| DAVID CHARLES SPANGLER New | — |
Pharmacy PHA
Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 S.930 - Allowing Greater Access to Safe and Effective Contraception Act S.1847/H.R. 3296 - Affordability is Access Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.6058 - SHOP SAFE Act of 2020 S.3431 - INFORM Consumers Act Legislation to increase domestic production of pharmaceuticals and the domestic supply chain. H.R. 6395 - National Defense Authorization Act for Fiscal Year 2021 S.4049 - National Defense Authorization Act for Fiscal Year 2021 HR 8179 - Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR HOLGATE | — |
| MARC SCHLOSS | — |
| DAVID CHARLES SPANGLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.